117718-92-0

Basic information

• Product Name: 3-BROMOIMIDAZO[1,2-A]PYRAZIN-8-AMINE
• Synonyms: 3-BROMOIMIDAZO[1,2-A]PYRAZIN-8-AMINE;8-AMino-3-broMoiMidazo[1,2-a]pyrazine
• CAS NO: 117718-92-0
• Molecular Formula: C₆H₅BrN₄
• Molecular Weight: 213.04
• Mol File: 117718-92-0.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Density: 2.098 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 3-BROMOIMIDAZO[1,2-A]PYRAZIN-8-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMOIMIDAZO[1,2-A]PYRAZIN-8-AMINE(117718-92-0)
• EPA Substance Registry System: 3-BROMOIMIDAZO[1,2-A]PYRAZIN-8-AMINE(117718-92-0)

Safety Data

• Hazardous Substances Data: 117718-92-0(Hazardous Substances Data)

Usage

General Description

3-Bromoimidazo[1,2-a]pyrazin-8-amine is a chemical compound that belongs to the class of organic compounds known as imidazo[1,2-a]pyrazines. These are polycyclic aromatic compounds containing an imidazo ring fused with a pyrazine ring. 3-Bromoimidazo[1,2-a]pyrazin-8-amine is particularly characterized by the presence of a bromine atom and an amine group (-NH2) at positions 3 and 8 of this polycyclic aromatic structure respectively. Its molecular formula is C7H5BrN4. While more research is needed to fully understand its potential applications, compounds in this chemical family have been associated with a variety of biological activities and could potentially be useful in medicinal chemistry and drug design.

Upstream product

• 69214-33-1 8-chloroimidazo[1,2-α]pyrazine 
• 63744-21-8 3,5-dibromoimidazo<1,2-a>pyrazine 
• 936361-36-3 3,8-dibromo-imidazo[1,2-a]pyrazine 
• 274-79-3 imidazo[1,2-a]pyrazine 
• 143591-61-1 3-bromo-8-chloro-imidazo[1,2-a]pyrazine 

Relevant articles and documents

Imidazo[1,2-a]quinoxalines for melanoma treatment with original mechanism of action

The malignant transformation of melanocytes causes several thousand deaths each year, making melanoma an important public health concern. Melanoma is the most aggressive skin cancer, which incidence has regularly increased over the past decades. We described here the preparation of new compounds based on the 1-(3,4-dihydroxyphenyl)imidazo[1,2-a]quinoxaline structure. Different positions of the quinoxaline moiety were screened to introduce novel substituents in order to study their influence on the biological activity. Several alkylamino or alkyloxy groups were also considered to replace the methylamine of our first generation of Imiqualines. Imidazo[1,2-a]pyrazine derivatives were also designed as potential minimal structure. The investigation on A375 melanoma cells displayed interesting in vitro low nanomolar cytotoxic activity. Among them, 9d (EAPB02303) is particularly remarkable since it is 20 times more potent than vemurafenib, the reference clinical therapy used on BRAF mutant melanoma. Contrary to the first generation, EAPB02303 does not inhibit tubulin polymerization, as confirmed by an in vitro assay and a molecular modelisation study. The mechanism of action for EAPB02303 highlighted by a transcriptomic analysis is clearly different from a panel of 12 well-known anticancer drugs. In vivo EAPB02303 treatment reduced tumor size and weight of the A375 human melanoma xenografts in a dose-dependent manner, correlated with a low mitotic index but not with necrosis.

Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and?Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors

The transcription nuclear factor NF-κB plays a pivotal role in chronic and acute inflammatory diseases. Among the several and diverse strategies for inhibiting NF-κB, one of the most effective approach considered by the pharmaceutical industry seems to be

Methods for inhibiting protein kinases

The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim-1 kinase, and tyrosine kinase using imidazo[1,2-a]pyrazine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with protein kinases using such compounds.